Bimekizumab efficacy and safety in Chinese patients with psoriasis in the <scp>BE SHINING</scp> Phase 3 study

Bimekizumab treatment was well tolerated and led to significantly higher clinical response rates versus placebo, including complete skin clearance, in Chinese patients with moderate to severe psoriasis. Findings were consistent with global studies.